ATLANTA, GA – – (Globe Newswire – July 31, 2026) – – A shareholder class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor”) (NASDAQ: CAPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Capricor adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel; (2) the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel Biologics License Application; (3) as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; and (4) as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy.

If you purchased Capricor shares between December 17, 2025 and July 26, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/capricor/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is September 28, 2026.